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Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), resulted in an unprecedented global crisis. Although
primarily a respiratory illness, dysregulated immune responses may lead to multi-organ
dysfunction. Prior data showed that the resident microbial communities of gastrointestinal
and respiratory tracts act as modulators of local and systemic inﬂammatory activity (the
gut–lung axis). Evolving evidence now signals an alteration in the gut microbiome, brought
upon either by cytokines from the infected respiratory tract or from direct infection of the
gut, or both. Dysbiosis leads to a “leaky gut”. The intestinal permeability then allows
access to bacterial products and toxins into the circulatory system and further
exacerbates the systemic inﬂammatory response. In this review, we discuss the
available data related to the role of the gut microbiome in the development and
progression of COVID-19. We provide mechanistic insights into early data with a focus
on immunological crosstalk and the microbiome’s potential as a biomarker and
therapeutic target.
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INTRODUCTION
Since it was ﬁrst recognized, Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), remains a global afﬂiction (1). Although
vaccines offer hope in curbing the pandemic (2), an improved understanding of its pathogenesis and
concurrent efforts to explore preventive and therapeutic strategies remain a priority to consolidate
the success of mass vaccination and herd immunity.
The clinical spectrum of COVID-19 ranges from asymptomatic to severe, life-threatening
disease (3). Current understanding of pathogenesis postulates a rapid and intense hyperactivation of
the immune system, resulting in critical illness and mortality (4). Older age, burden of
comorbidities, obesity, immunocompromised states, malignancy or ongoing cancer treatment,
and being a transplant recipient, have been strongly linked with severe, and sometimes fatal,
outcomes (5–9). Evolving data suggest that a state of chronic inﬂammation or baseline activation of
the immune system might inﬂuence the course of COVID-19 more than direct cytopathic effects of
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An imbalanced state is described as “gut dysbiosis”, a condition
characterized by an alteration in the abundance or composition
of the microbiota. Gut dysbiosis may occur with aging, dietary
effects, drugs, gastrointestinal infections, and anatomical
alterations of the GIT. A signiﬁcantly dysbiotic state may
predispose to the diseases of GIT, such as Clostridioides difﬁcile
enterocolitis, which is associated with prolonged and recurrent
broad-spectrum antibiotic usage (20). Since gut microbiota
modulates the ﬁne balance between pro- and antiinﬂammatory systemic responses, a dysbiotic state has also
been associated with non-gastrointestinal systemic illnesses
such as malignancy (12), type 2 diabetes mellitus (21), nonalcoholic steatohepatitis (22), coronary artery disease (23),
neurodegenerative diseases (24), and depression (25).

the SARS-CoV-2. Furthermore, a subgroup of patients have been
noted to develop auto-inﬂammatory symptoms (such as
Kawasaki-like disease in children and multi-system
inﬂammatory syndrome) long after clearance of the SARSCoV-2 virus from body, suggesting an immune dysregulation
(8, 10).
In the human body, the gastrointestinal tract (GIT) is the
largest immune organ (11). The pool of resident microorganisms
(bacteria, viruses, and fungi) in the GIT, collectively known as
the gut microbiota, not only supports mucosal immunity but also
modulates the systemic immune response of the host (12).
Current evidence from other respiratory illnesses indicates that
the gut microbiota affects the immunity and inﬂammation in the
lungs (13, 14). Lately, some studies have examined the
association between gut microbiota and SARS-CoV-2. In this
review, we present the existing data related to the intersection of
gut microbiome and the host’s immune response to SARSCoV-2. We further explore the role of gut microbiome
diversity and its compositional differences as diagnostic
biomarkers, and the potential of the gut microbiome as an
interventional target in modifying COVID-19 outcomes.

THE GUT–LUNG AXIS
The GI and respiratory tracts share a common mucosal immune
system, known as the gut–lung axis (26, 27). From birth, both
tracts receive their quota of microbiota via the oral route (28), and
subsequently establish a differing but internally quasi-stable genre
of microorganisms or microbiota (29). Although the microbiota of
both tracts consists of similar phyla, they differ at the level of
species in composition and density. Understandably, studies on
respiratory microbiota have been complicated by tedious and
invasive methods for collection of uncontaminated lower
respiratory samples, and most data have been derived from mice
models where lung tissue can be aseptically obtained (30).
Consequently, there is growing excitement in understanding this
complex immunological intersection.
Throughout the lifespan of an individual, established
microbiota of both tracts contribute to the gut–lung axis,
modulating both local and systemic immune responses when
faced with a pathogenic threat. The axis is believed to be
bidirectional, affecting the immune response of either tract
when one site is activated (31). Using a germ-free murine
model, Ichinohe et al. demonstrated potentially deleterious
effects on respiratory immune responses after alteration of the
gut microbiota with antibiotics (32). Other studies have also
found that gut microbiota alterations result in abnormal
activation of the immune system, predisposing to respiratory
illnesses such as asthma, lung allergic responses, and chronic
respiratory diseases (27, 33). Conversely, animal studies have
also revealed an alteration in the gut microbiota after respiratory
viral and bacterial infections (34–36). This distant effect is
believed to be communicated by activation of the systemic
immune system, with dysbiosis of either tract feeding into
the other.

SIGNIFICANCE OF GUT MICROBIOTA
The human GIT is home to about 10 4–105 bacteria per
millimeter of content in the small intestine, and 1011 bacteria
per gram of colonic content (15). In a healthy person, the gut
microbiota comprises more than 100 bacterial phyla and the
majority of bacteria belong to Firmicutes, Bacteroidetes,
Proteobacteria, and Actinobacteria, with Firmicutes and
Bacteroidetes phyla constituting over 90% of the entire gut
microbiota (16). The microorganisms and their combined
genetic material make up the gut microbiome, which
outnumber the human genome by about 150 times (17). The
proportion of the various phyla remains quasi-stable and unique
for an individual, although a shift can be observed during a
change in health status. For example, the gut microbiome in the
elderly has been observed to drift away from Firmicutes and
towards Proteobacteria and Alistipes (18).
The gut microbiota exists in a symbiotic relationship with its
host. It facilitates the synthesis of vitamins and fermentation of
carbohydrates and other undigested nutrients and aids in the
delivery of essential nutrients like short-chain fatty acids (SCFAs)
to colonic epithelial cells. In addition, it also regulates mucosal
permeability and provides deterrence against pathogenic
microbes. More importantly, the microbiota plays an
indispensable role in the preservation of intestinal homeostasis
by modulating local and systemic immune responses of the host
(19). The microbiota protects the GIT by (a) acting as a competitor
against binding of pathogenic microbes, (b) neutralizing
pathogens with their anti-microbial metabolites, (c) keeping the
local immune system in a perpetual vigilant state, and (d)
regulating the innate and adaptive immunity.
In a healthy person, the proportion of the various phyla
mostly remains quasi-stable and unique for an individual (18).
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ROLE OF GUT MICROBIOTA IN
RESPIRATORY VIRUS INFECTION
While the immune-related interactions between resident gut and
respiratory tract microbiota are yet to be explored, a conceptual
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understanding of the impact of the gut microbiota in patients with
COVID-19 may be extrapolated by examining the existing evidence
of its role in non-SARS-CoV-2 respiratory virus infections.

infection and an alteration in the gut and respiratory tract
microbiota, with the presence of inﬂammation of the GIT.

Evidence From SARS-CoV-1 Infection

ROLE OF GUT MICROBIOTA IN THE
PATHOGENESIS OF COVID-19

Many respiratory viral illnesses are commonly accompanied by
GI symptoms. Previous studies during the severe acute
respiratory syndrome (SARS) outbreak in 2002 showed that
diarrhea was a common symptom and occurred in 16%–73%
of patients. The Severe Acute Respiratory Syndrome Coronavirus
(SARS-CoV-1) was not only known to infect the lung epithelial
cells but also the immune cells, triggering an intense immune
response with elevation in Th2 cytokines (37). It was postulated
that high levels of circulating pro-inﬂammatory cytokines altered
the gut microbiota and compromised intestinal integrity. The
resultant “leaky” gut allowed translocation of bacterial products
and antigens into the circulation, further exacerbating the illness
(38). Due to the bidirectional nature of the gut–lung axis, an
alteration in gut microbiota further augments the respiratory
immune responses, conceivably resulting in a vicious
perpetuation of systemic inﬂammatory response (32).

Although no speciﬁc interaction between any gut microbial
species and SARS-CoV-2 has been identiﬁed to date, there is
indirect evidence (44, 45) that gut microbiota may have a role in
the overall pathogenesis of COVID-19, as summarized in
Figure 1. Taking the corollary further from non-SARS-Cov-2
virus-mediated gut dysbiosis, it is conceivable that infection with
SARS-CoV-2 may also be impacted by immunological
interactions with the gut microbiota.

Pathogenesis of GI Symptoms
in COVID-19
About half of patients with COVID-19 develop GI symptoms,
which often precede the respiratory symptoms (45). In the
respiratory tract, the SARS-CoV-2 infects the alveolar cells by
binding to angiotensin-converting enzyme 2 (ACE-2) receptors.
Interestingly, these receptors are also abundantly expressed on
the surface of enterocytes (46), where they play an important role
in maintaining the homeostasis of microbiota and mucosal
inﬂammation (47). In one patient with COVID-19, Xiao et al.
detected SARS-CoV-2 RNA, viral nucleocapsid protein, and
ACE-2 in the epithelial cells of the esophagus, stomach,
duodenum, and rectum (48). Several authors have also
reported detection of SARS-CoV-2 RNA fragments, but not
the whole virus, in stool samples (49, 50). A study by Lamers
et al. also demonstrated that SARS-CoV-2 was able to infect
enterocyte lineage cells in a human intestinal organoid model
(51). Unfortunately, due to the scarcity of autopsy studies and
pragmatic restrictions on endoscopic examinations of the GIT,
there are only limited data to support this hypothesis in vivo. It
also remains unknown how SARS-CoV-2 may survive the acidic
gastric environment to directly infect enterocytes. Overall, it is
unclear whether the GI symptoms of COVID-19 are a result of
primary infection of the GIT or derived from other indirect
mechanisms mentioned below.

Evidence From Other Community
Respiratory Viruses
Using a mouse-model, Deriu et al. demonstrated that respiratory
viral infection due to inﬂuenza resulted in gut dysbiosis
predisposing to secondary Salmonella infection via circulatory
type I interferons (34). Similarly, Wang et al. demonstrated
indirect intestinal inﬂammation with inﬂuenza infection in a
mouse-model occurring via microbiota-mediated Th17 celldependent inﬂammation (36). Several studies have reported
gut dysbiosis after respiratory viral infection (39, 40). Groves
et al. showed that gut dysbiosis, in the form of an increase in
Bacteroidetes and a decrease in Firmicutes phyla abundance,
occurred in mice models with respiratory syncytial and
inﬂuenza virus infections, but not in those vaccinated with live
attenuated inﬂuenza viruses (41). Furthermore, elevated levels of
colonic Muc5ac and fecal lipocalin-2 in the pathogenic infection
group suggest the presence of low-grade gut inﬂammation
during respiratory virus infection.
Respiratory virus infection may also cause dysbiosis in lung
microbiota, modulating both local immune responses within the
lung parenchyma and systemically. Due to the difﬁculties in
sampling of lung microbiota, only a few studies have examined
the role of respiratory pathogens in altering lung microbiota.
Molyneaux et al. reported an increased proportion of
Proteobacteria and potentially pathogenic Haemophilus inﬂuenzae
in the lower respiratory tract microbiota in rhinovirus-infected
patients with chronic obstructive pulmonary disease (42). Using a
mouse-model inoculated with intranasal H1N1 inﬂuenza virus, Gu
et al. demonstrated a bacterial class shift in the lung microbiota,
which persisted even during the recovery period (43).
Notwithstanding the limitations in available studies, a common
theme has emerged showing a link between respiratory virus
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Fecal Shedding of SARS-CoV-2
SARS-CoV-2 is principally transmitted by respiratory droplets,
but evidence is accumulating for fecal-oral transmission. The
hypothesis is supported by the presence of GI symptoms,
detection of SARS-CoV-2 nuclear ﬁngerprints in the GI
mucosa, and detection of viral fragments in fecal samples.
Interestingly, the ﬁrst COVID-19 patient in the United States
tested positive for SARS-CoV-2 via stool samples (52), and
subsequent studies have consistently documented shedding of
viral RNA in the stool samples in COVID-19 patients (53, 54).
Furthermore, viral shedding in stool samples has been observed
to persist longer than that in respiratory samples (55, 56).
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FIGURE 1 | SARS-CoV-2 and the lung–gut axis: SARS-CoV-2 virus enters the alveolar cells by binding with ACE2 receptors, which are also abundant on the
surface of enterocytes. The implication of direct infection of enterocytes by SARS-CoV-2 is still being explored. The circulatory cytokines from alveolitis (and/or direct
viral infection of the enterocytes) cause the GI dysbiosis with resultant alterations in GI mucosal barrier. The entry of bacterial products and toxins from the GIT ﬂoods
the circulatory system with more pro-inﬂammatory cytokines. Image was created with Biorender.com.

signiﬁcantly reduced bacterial diversity, increased abundance
of opportunistic pathogens (such as Streptococcus, Rothia,
Veillonella, and Actinomyces), and signiﬁcantly less diverse
symbiotic species. Interestingly, the altered microbial signature
in COVID-19 was different from patients with the H1N1 strain.
In another study, Zuo et al. analyzed fecal samples of 15
patients with COVID-19 using shotgun metagenomic
sequencing (62). The study revealed a marked increase in
opportunistic pathogens and depletion of beneﬁcial microbes
as compared to healthy controls, which persisted even after
clearance of SARS-CoV-2. These ﬁndings suggest an inverse
correlation between gut dysbiosis and COVID-19 severity and
are congruent with the conclusions of a larger multi-center study
in which Yeoh et al. examined the gut microbiota in 100 patients
using shotgun sequencing. Fecal samples from 27 patients were
analyzed longitudinally over 30 days, showing signiﬁcant
dysbiosis that persisted despite clearance of SARS-CoV-2.
Correlative blood samples demonstrated an association
between gut dysbiosis, elevation in the inﬂammatory
mediators, and severity of systemic inﬂammation (63).
Another study by Newsome et al. compared microbiota
composition from stool samples of 50 COVID-19 patients with
uninfected patients (64). Signiﬁcant perturbations in the
microbiota composition in the COVID-19 patients were
observed, independent of antibiotic exposure. The gut

Hypercytokinemia and the Leaky Gut
Elevated serum levels of pro-inﬂammatory markers, such as
interleukin-6 (IL-6) and interleukin-10 (IL-10), are hallmarks
of severe COVID-19 infection (57). These cytokines predispose
to dysbiosis, which consequently alters intestinal permeability, a
state known as the “leaky gut”. This enables further entry of a
multitude of bacterial products and toxins, activating a proinﬂammatory cascade. In a study in 204 patients with COVID19, Pan et al. reported that GI symptoms worsened with
increasing severity of COVID-19 (58). In another study, fecal
calprotectin levels (a marker of GI mucosal inﬂammation) were
elevated in patients who had diarrhea during COVID-19 illness
(59). A recent study by Prasad et al. measured several markers of
gut permeability in the plasma (60). Levels of FABP2, PGN, and
LPS were signiﬁcantly higher among COVID-19 patients
compared to healthy subjects, suggesting translocation of proinﬂammatory antigens from a leaky gut.

Association Between Gut Dysbiosis and
Systemic Inﬂammation
Gu et al. ﬁrst presented evidence of an altered gut microbiota in
COVID-19 patients by using high-throughput sequencing of 16S
ribosomal RNA to compare the gut taxa of patients with
COVID-19, H1N1 inﬂuenza, and healthy controls (61).
Compared to healthy controls, COVID-19 patients had
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“metabolome”, a biochemical signature derived from bacterial
metabolic activity in the gut, is another method for detecting an
alteration in the gut microbiota composition. In a recent study by
Lv et al., fecal samples of COVID-19 patients had altered
metabolomes, suggesting malnutrition and intestinal
inﬂammation (65). These results provide new insights into the
pathogenesis of COVID-19.

due to the existence of less virulent strains of SARS-CoV-2, or the
protection from adaptive immunity given the novel nature of the
virus, the immune response of the host remains the most probable
factor in determining disease severity. It is unclear if any speciﬁc
pattern of gut microbiota protects individuals from mounting a
severe inﬂammatory state when infected with SARS-CoV-2. Kumar
et al. highlighted a potential link between the environmental
microbiota of a population and the burden of COVID-19. With
data from 122 diverse countries, lower COVID-19-associated
mortality was observed in countries with a higher percentage of
rural population (alluding to higher gut microbial diversity), higher
proportion of population residing in slums, and a lower water
quality and sanitation score (69). While such observational data can
be prone to confounders, these results offer some insight into the
potential role of gut microbiota on the disease burden of
COVID-19.

Gut Dysbiosis as a Biomarker of
Viral Replication
Although it was previously believed that gut dysbiosis in
COVID-19 was mainly driven by inﬂammatory mediators
from respiratory tract infection, a recent study suggests that
active replication of SARS-CoV-2 in the gut may be driving the
dysbiosis (66). Using in vitro transcriptional analysis in a SARSCoV-2-infected cell model (with samples obtained from stools),
the 3’ end of the SARS-CoV-2 genome was detected more than
the 5’ end, suggesting active viral replication. Interestingly,
majority of the patients had no GI symptoms, suggesting a
quiescent GI infection despite active replication of SARS-CoV2 in the GIT with dysbiosis. Moreover, on functional analysis of
the gut microbiota, fecal samples with signatures of high SARSCoV-2 burden demonstrated high de novo nucleotide and amino
acid biosynthesis, correlating with increased bacterial
proliferation. Although this was a pilot study comprising only
15 patients, further studies on alterations in the functionality of
the gut microbiota may unearth the pathophysiology of COVID19 illness.
Overall, currently expanding evidence suggests that patients
with COVID-19 suffer from an alteration in the gut microbiota
during and after the illness. Both systemic inﬂammation and
replicative potential of SARS-CoV-2 in the gut may contribute
towards dysbiosis.

Gut Microbiota in Severe COVID-19
There is mounting evidence that being elderly and having a chronic
inﬂammatory state (from chronic medical conditions) predisposes
to a pro-dysbiotic state (70, 71). It is unlikely a coincidence that the
highest rates of morbidity and mortality from COVID-19 have also
been observed in the elderly, those with underlying chronic medical
conditions, and among immunosuppressed patients with cancers
(5–9). COVID-19 disease severity is likely host dependent and
driven by the inﬂammatory response. In autopsy samples from a
patient with severe COVID-19, inﬂammatory cells were observed in
the lungs (72), suggesting an intense inﬂammatory response (8).
Furthermore, studies have also reported elevated plasma levels of
pro-inﬂammatory cytokines such as interleukin-1 (IL-1), IL-6, and
tumor necrosis factor alpha (57, 73), in severe COVID-19. In
patients prone to gut dysbiosis, further inﬂammatory triggers may
tip the balance over to a leaky gut, resulting in a self-perpetuating
inﬂammatory feedback circle. Notably, two small studies showed a
direct correlation between severe COVID-19 and gut dysbiosis (62,
63) Another two studies have shown that patients with severe
COVID-19 experienced more pronounced GI symptoms, along
with higher levels of stool calprotectin (an indicator of GI
inﬂammation and disrupted mucosal integrity) (58, 59). This
supports the concept of an immunological crosstalk between the
lungs and gut, presumably moderated by the gut microbiota (12).
There is still a lack of data assessing the role of gut microbiota in a
high-risk cohort (such as elderly or cancer patients) with
COVID-19, although a study on the impact of probiotics on
health and immunity in elderly and diabetic patients, and
response to COVID-19 vaccination, is underway (Table 3).

CLINICAL IMPLICATION OF GUT
MICROBIOTA IN COVID-19
Though limited in number, studies to date have consistently
demonstrated gut dysbiosis in patients with COVID-19 (Table 1).
A more important clinical implication lies in understanding
whether, and how, gut microbiota predisposes to varying degrees
of COVID-19 severity.

Potential Role of Gut Microbiota in
Asymptomatic/Subclinical and
Mild COVID-19
As previously mentioned, clinical spectrum of COVID-19 ranges
from asymptomatic to severe, life-threatening disease (3). A recent
systematic review demonstrated that about one-third of patients
remain clinically asymptomatic after infection with SARS-CoV-2
(68). However, a possibility of subclinical inﬂammatory process
remains. In a systematic review involving 231 asymptomatic
COVID-19 patients, almost two-thirds (63%) had inﬂammatory
changes in the lungs on computed tomography (CT) scan (67).
Irrespective of subtle inﬂammatory changes, a subset of patients
may not mount the intense inﬂammatory response that portends
severe illness. As this heterogeneity in clinical severity is less likely
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THERAPEUTIC POTENTIAL OF GUT
MICROBIOME FOR COVID-19
Given the association between gut dysbiosis and COVID-19
severity, the therapeutic potential for modulation of the gut
microbiome to modify disease outcomes holds promise. However,
there is no microbiota-directed therapy that has demonstrated
efﬁcacy in preventing the development or progression of COVID19 currently.
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TABLE 1 | Studies exploring the role of gut microbiota in COVID-19.
Authors

Study
design

Zuo et al.
(62)

Single
center,
prospective

Gu et al.
(61)

Singlecenter,
crosssectional

Yeoh
et al. (63)

Prospective
cohort
study from
two centers

Zuo et al.
(66)

Prospective
cohort
study from
two centers

Tsikala
et al. (67)

Crosssectional
(A
statement
across 122
countries)

Prasad
et al. (60)

Prospective
cohort
study from
one center

Newsome
et al. (64)

Prospective
cohort

Study population

Salient ﬁndings

Analyses/methods

Limitations

Small sample size.
Only hospitalized
patients with
moderate to severe
COVID-19.
>50% patients with
COVID-19 had
received antibiotics.
16S ribosomal RNA gene sequencing for
Signiﬁcantly reduced bacterial diversity
Small sample size.
proﬁling of GI microbiota
(dysbiosis) with COVID-19, a signiﬁcantly higher Healthy controls
relative abundance of opportunistic pathogens, matched for age, sex,
and a lower relative abundance of beneﬁcial
and BMI but not for
symbionts. Patients with H1N1 displayed lower diet and lifestyle
diversity and different overall microbial
factors.
composition compared with COVID-19
H1N1 cohort had
patients.
been hospitalized for
severe illness,
compared to COVID19 cohort which had
disease severity
classiﬁed as “general”
and “severe”.
Shotgun sequencing of stool DNA for
Signiﬁcant alterations in the GI microbiota
Heterogeneous
100 COVID-19
proﬁling of GI microbiota. Assessment of
(dysbiosis) in COVID-19 patients.
clinical management
compared against
healthy controls
serum levels of inﬂammatory markers.
Dysbiosis persisted even after 30 disease post of patients.
illness.
30-day changes were
Signiﬁcant correlation of dysbiosis with severity studied in 27 (out of
of COVID-19 illness and with various serum
100) patients
pro-inﬂammatory markers.
15 hospitalized
RNA shotgun metagenomics for proﬁling of
Detection of alterations in GI microbiota
Small sample size.
patients with
GI microbiota. Assessment of functionality of (dysbiosis) with high markers of bacterial
Exact role of various
COVID-19
GI microbiota and detection of replicative
cellular building.
microbiota proﬁles in
activity of SARS-CoV-2 virus in the GI tract. 46.7% patients had stool positivity for SARSdetermining severity
CoV-2, even in the absence of GI
of COVID-19 infection
manifestations.
needs further studies
High replicative activity of SARS-CoV-2 in the
GI tract suggesting.
42 low- or lowStatistical analysis comparing deaths per
A statistically signiﬁcant negative correlation
Cross-sectional data
middle-income
million secondary to COVID-19 infection,
was observed between COVID-19 mortality
based on national
countries
against population health indicators like
and populations that had a high percentage of population health
indicators.
compared against
water current score, health efﬁciency,
rural residents, and a high proportion of
Inferential hypothesis
80 high- or upper- percentage rural population, proportion of
diarrhea secondary to inadequate sanitation.
middle-income
diarrhoea cases secondary to inadequate
As a result, a high microbial exposure to gram- based on effect of
environmental
countries
sanitation and healthy life expectancy (HALE) negative bacteria was proposed to confer
microbiological
at birth.
protective effects against COVID 19, possibly
prevalence rather than
due to increased interferon type I levels.
direct sequencing of
human GI microbiota
samples.
No analysis of
interferon type-I levels
in study populations.
30 hospitalized
Microbial DNA extraction and 16S rRNA
In the plasma samples of about 65% patients
Small sample size.
patients with
sequencing in the plasma samples. Levels of with COVID-19, abnormal signatures of gut
One-time collection of
COVID-19 and 16
gut permeability markers were also
microbes were seen. As compared with the
the plasma.
healthy subjects.
measured.
healthy controls, patients with COVID-19 had
Absence of
signiﬁcantly elevated plasma levels of gut
demonstration of gut
permeability markers (such as FABP2, PGN,
dysbiosis in the
and LPS).
stools.
50 hospitalized
16S rRNA sequencing and qPCR analysis
The fecal microbial composition was
Small sample size.
COVID-19 patients, was performed on fecal DNA/RNA.
signiﬁcantly different in the currently infected
Cross-sectional
9 recovered
COVID-19 patients. The COVID-19 patients
sampling.
15 COVID-19
patients in Hong
Kong compared
against 6 subjects
with communityacquired
pneumonia and 15
healthy individuals
30 COVID-19
patients compared
against 24 H1N1
patients and 30
matched healthy
controls

Shotgun metagenomic sequencing for
proﬁling of GI microbiota

Signiﬁcant alterations in GI microbiota
(dysbiosis) in COVID-19 patients
Persistent dysbiosis despite clearance of
SARS-CoV-2
Positive correlation between dysbiosis and
severity of COVID-19

(Continued)
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TABLE 1 | Continued
Authors

Lv et al.
(65)

Study
design

Study population

study from
one center

patients and 34
uninfected
subjects.

Prospective
cohort
study from
one center

56 hospitalized
COVID-19 patients
and 47 age- and
sex-matched
healthy subjects.

Salient ﬁndings

Analyses/methods

Stool samples were analyzed for various
microbial biochemical products (or
metabolome) using gas chromatography–
mass spectrometry.

Small sample size.
Absence of
demonstration of gut
dysbiosis in the
stools.
No control for diet
and anti-microbial
agents.

secondary bacterial infections (83). Given the dearth of data
pertaining to SARS-CoV-2 and the relative safety of probiotics,
the rapid promulgation in favor of probiotics seems reasonable
while awaiting further evidence. Although there is no direct
evidence yet showing the efﬁcacy of any speciﬁc strain of
probiotic against COVID-19, several registered trials are currently
examining the therapeutic potential of various probiotics
formulations in COVID-19 (Table 3).

Potential Role of Prebiotics
Plant-based ﬁbers exert a prebiotic effect by promoting the growth
of beneﬁcial microorganisms in the gut microbiota (e.g.,
Biﬁdobacterium and Lactobacillus spp.) while decreasing the
proportion of harmful species (e.g., Clostridia) (74). Moreover, the
fermentation of soluble dietary ﬁbers by certain bacterial species
yields several beneﬁcial metabolites, such as SCFAs, which serve to
maintain colonic mucosal integrity and modulate the immune
system (75). By-products of SCFAs are also absorbed into the
circulatory system and have anti-inﬂammatory effects. In mice
models, a high-ﬁber diet with elevated SCFA levels was protective
against allergic inﬂammation in the lungs, while a low-ﬁber diet
with decreased SCFA levels resulted in increased allergic airway
disease (76). Interestingly, studies from other respiratory diseases
have demonstrated a reduction in mortality with intake of whole
grains (77, 78). Although the beneﬁcial effects of dietary ﬁbers are
intuitive, there is currently no direct evidence that any speciﬁc
amount or type of dietary ﬁber is beneﬁcial in COVID-19 illness.

Potential Role of Fecal Microbiota
Transplantation
FMT is a process of actively transferring colonies of fecal bacteria
from a healthy person into the GIT of another individual. The
process aims to restore the composition of gut microbiota back to a
healthy state. As mentioned earlier, FMT is an effective therapy for
recurrent or refractory C. difﬁcile enterocolitis (84). Given the
proposed role of gut microbiota in the abnormal activation of
immune responses in the COVID-19, FMT can potentially be
explored as a therapeutic strategy. A recent case report (85)
described two patients with rapid resolution of COVID-19 after
FMT was undertaken to treat concomitant C. difﬁcile infection.
However strong may be the hypothesis and surrounding
speculations, FMT should not presently be recommended as a
therapy against COVID-19 due to the scarcity of large-scale studies.
To explore further, a clinical trial (FeMToCOVID) is currently
registered at the clinicaltrials.org (NCT04824222), though it has not
yet started recruiting patients.

Potential Role of Probiotics
Oral probiotics are live bacteria of speciﬁc species that alter the
composition of gut microbiota after reaching the intestines (74). A
shift to beneﬁcial bacterial species modulates the local and systemic
inﬂammatory balance, with several studies demonstrating a positive
impact on respiratory infections and other extra-intestinal illnesses.
Using a probiotic bacterium, Lactobacillus gasseri SBT2055 in
mouse models, prevention of infection with respiratory syncytial
virus was demonstrated (79). In another study on 30 elderly
volunteers, Biﬁdobacterium lactis HN019 ingestion was shown to
enhance the cellular immunity (80). Placebo controlled clinical trials
with probiotics (using Lactobacillus rhamnosus GG, Bacillus subtilis,
and Enterococcus faecalis) have also demonstrated signiﬁcant
improvement in patients with ventilator-associated pneumonia
(81, 82).
Naturally, if dysbiosis is indeed involved in the pathogenesis of
severe COVID-19, probiotics appear to be among the more
convenient, efﬁcient, and potentially safe strategies. After initial
reports of gut dysbiosis in patients with severe COVID-19, the
National Health Commission (of China) recommended the use of
probiotics to maintain gut microbial homeostasis and prevent

Frontiers in Immunology | www.frontiersin.org

had increased relative abundance of
Campylobacter and Klebsiella, two genera
associated with GI disease. The microbiota
composition was similar between recovered
and uninfected patients.
Differences in the metabolomes of COVID-19
patients were observed compared with healthy
controls.

Limitations

UNANSWERED QUESTIONS AND FUTURE
DIRECTIONS
Despite the efﬁcient pace of clinical trials evaluating new and
repurposed agents for COVID-19, success has been modest at
best. Although still in nascent stages, evolving evidence signals a
probable link between gut microbiota and the host’s immune
response to COVID-19. However, the exact mechanism and
extent of the role of gut dysbiosis in disease severity remain to be
elucidated. This is further compounded by the inherent
challenges associated with designing microbiome studies.
Another possible angle would be to deﬁne the state of a leaky
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TABLE 2 | Unanswered questions and potential research methodology.
Category

Question

Susceptibility to infection with
SARS-CoV-2
Onset of symptoms after
infection with SARS-CoV-2
Development of severe
COVID-19 illness
Alteration in gut microbiota by
the SARS-CoV-2
Persistence of gut dysbiosis
after SARS-CoV-2
Alteration in intestinal
permeability with SARS-COV2
Therapeutic and preventive
roles of prebiotics and
probiotics
Therapeutic role of FMT in
COVID-19

Potential methodology

Does gut microbiota play a role in the onset of
infection with SARS-CoV-2?
Does gut microbiota inﬂuence development of
symptoms in COVID-19?
Does pre-existing gut microbiota predispose to
different levels of severity?
Does gut microbiota get altered by the SARSCoV-2?
Is SARS-CoV-2-induced gut dysbiosis
temporary?
Does SARS-CoV-2-led inﬂammation lead to
alteration in intestinal permeability.

To characterize the diversity of gut microbiome across separate cohorts of
individuals with varying risk of exposure to SARS-CoV-2.
To study differences of gut microbiome between asymptomatic and
symptomatic individuals.
To examine the baseline gut microbiota and correlate with severity of COVID-19
illness.
To evaluate the temporal trend of gut microbiome in the COVID-19 illness.

Do prebiotics and/or probiotics have potential to
alter course of COVID-19 illness?
Can a reset of gut dysbiosis to normal
homeostasis with the FMT mitigate severe
COVID-19 illness?

To examine the long-term trend in the gut dysbiosis and its associated
implications.
Detection and measurement of gut-derived bacteria and/or their bacterial
products in the circulation or extra-intestinal tissues (such as mesenteric lymph
nodes).
Assessing variety of probiotics in terms of prevention and optimization of
COVID-19 illness.
To assess the potential therapeutic role of the FMT in severe COVID-19 illness.

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2); COVID-19 (Coronavirus disease 2019); GI (gastrointestinal); FMT (fecal microbiota transplantation).

TABLE 3 | Ongoing registered trials studying role of gut microbiota in COVID-19 (updated as of June 19, 2021).
A. Ongoing observational studies
Trial number

Title

Summary

NCT04669938 Role of the Microbiota in the Evolution of the SARS-CoV-2
Disease, COVID-19, in Hospitalized Patients
NCT04598334

NCT04597736

NCT04581135
NCT04552340

NCT04497402
NCT04475211
NCT04451577

NCT04410263

NCT04359836
NCT04359706

NCT04355741

NCT04332016

Observational study looking at the effect of oropharyngeal and gut microbiota, host
genotype, and immune characteristics and SARS-CoV-2 viral genome sequences on
outcomes of COVID-19 infection.
Cytokine Storm Among Bangladeshi Patients With COVID-19
Prospective study evaluating the relationship of inﬂammatory markers and cytokine
levels in addition to gut microbiota on COVID-19 infection severity in Bangladeshi
patients, at various points of illness progression.
Relationship Between Biological Proﬁles and Clinical Evolutions Cohort study examining the relationship between the biological proﬁles observed from
Within the Same Cluster COVID-19 (COVIDCOLLECT)
analysis of nasopharyngeal, saliva, blood, stool, and urine samples and the clinical
evolutions within the same cluster of COVID-19 cases and their contact subjects.
Study to Investigate Long-term Pulmonary and
Prospective study investigating long-term pulmonary and extrapulmonary effects of
Extrapulmonary Effects of COVID-19
COVID-19, including changes to gut microbiota.
Epidemiologic, Clinical and Molecular Characteristics of
Observational study examining factors including alveolar and nasal microbiota on
Patients With Acute Respiratory Failure Affected by 2019predisposition to SARS-CoV2 viral infection, symptomology, treatment response, and
NCOV
predisposition to complications.
Sex-Informed Data in the COVID-19 Pandemic
Observational study looking at differences in the biomarkers of different sexes during
SARS-CoV-2 infection, including the gut microbiome.
Predictors of Mortality at Day 28 of Patients Treated at Lille
Retrospective observational study to evaluate predictive factors of mortality at day 28
University Hospital for COVID-19
in COVID-19 patients treated at a single center.
Epidemiologic, Clinical, Molecular Characteristics of Hospital
Case–control study evaluating biological samples obtained from hospital employees to
Employees With or Without COVID-19 Infection
characterize SARS-CoV-2 pathogenesis and individual differences in susceptibility to
the disease.
Microbiota in COVID-19 Patients for Future Therapeutic and
Observational study analyzing biological samples including nasopharyngeal and
Preventive Approaches
alveolar microbiota to elucidate risk factors for the development of severe ARDS in
SARS-CoV-2 infected patients.
A Study to Explore the Role of Gut Flora in COVID-19 Infection Observational study aiming to sequence and characterize the gut microbiome of
COVID-19 patients during and after treatment.
Bacterial and Fungal Microbiota of Patients With Severe Viral
Observational study comparing the respiratory and gut microbiota and inﬂammatory
Pneumonia With COVID-19
markers of critically ill COVID-19 patients with historical critically ill patients without
COVID-19.
Gut Microbiota, “Spark and Flame” of COVID-19 Disease
Observational study analyzing and comparing the gut microbiome of COVID patients
across settings in the intensive care unit, hospital general ward, and self-caring at
home.
COVID-19 Biological Samples Collection
Observational collection and analysis of biological samples including gut microbiota of
patients with COVID-19 infection and their caregivers.
(Continued)
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TABLE 3 | Continued
A. Ongoing observational studies
Trial number

Title

NCT04325919 Coronavirus Disease 2019 (COVID-19) Study of Hospitalized
Patients in Hong Kong
NCT04708912 Nasopharynx Microbiota Component and in Vitro Cytokines
Production in Coronavirus Disease (COVID-19)
NCT04768244 Impact of Maternal COVID-19 Disease on Breast Milk and
Infant Health (MilkCorona)
NCT04913142 About Oral and Gut Microbiota in Intensive Care Unit: SARSCoV-2 (COVID-19) Infection Impact (CO-MIC)
NCT04813328 A Pilot Study of the Effects of Helminth Infection and SARSCoV-2 Seropositivity on Immune Response and the Intestinal
Microbiota in India

Summary
Observational study characterizing clinical, virological, microbiological, and
immunological proﬁles of COVID-19 infection compared against patients hospitalized
for pneumonia.
Observational study comparing nasopharynx microbiota composition, RNA
sequences, and in vitro cytokine production in COVID-19 patients with mild-moderate,
severe, convalescent disease and healthy controls.
Prospective study assessing the impact of maternal COVID-19 on immune,
microbiological, and metabolic proﬁle of breast milk and infant microbiota, growth, and
development.
Prospective cohort study to describe the impact of SARS-CoV-2 infection on the oral
and gut microbiota of ICU patients, and to compare against the microbiota of nonCOVID-19 ICU patients.
Cross-sectional study to characterize the immune response and intestinal microbiota
in people with and without SARS-CoV-2 antibodies and helminth infection.

B. Ongoing studies utilizing microbiota as therapeutic target
Trial number

Title

NCT04666116 Changes in Viral Load in COVID-19 After Probiotics
NCT04621071 Efﬁcacy of Probiotics in Reducing Duration and Symptoms of
COVID-19
NCT04581018 An Evaluation of a Synbiotic Formula for Patients With COVID19 Infection
NCT04517422 Efﬁcacy of L. Plantarum and P. acidilactici in Adults With
SARS-CoV-2 and COVID-19

Summary
Randomized clinical trial evaluating the capacity of a novel nutritional supplement
intervention in decreasing SARS-CoV-2 viral load by nasopharyngeal swab
Randomized controlled trial to evaluate the efﬁcacy of probiotics in reducing the
duration and symptoms of COVID-19 in a symptomatic population tested positive to
SARS-CoV-2, self-caring at home
Non-randomized clinical trial examining effect of a synbiotic health supplement on
COVID-19 symptoms
Randomized controlled trial to study ability of a probiotic to reduce progression of mild
COVID-19 infection to moderate/severe disease and other prognostic factors,
including gastrointestinal symptoms and gut microbiome composition
Randomized trial evaluating effects of a novel glycan on the gut microbiota of
outpatients with COVID-19.

NCT04486482 A Clinical Study to Assess the Physiologic Effects of KB109 in
Patients With COVID-19 on Gut Microbiota Structure and
Function
NCT04479202 The Effect of Berberine on Intestinal Function and Inﬂammatory Double-blinded randomized trial analyzing the effect of berberine on gut microbiota,
Mediators in Severe Patients With COVID-19
gastrointestinal manifestations, and inﬂammatory markets in patients with severe
COVID-19.
NCT04420676 Synbiotic Therapy of Gastrointestinal Symptoms During
Clinical trial comparing a probiotic mixture to placebo in alleviating gastrointestinal
COVID-19 Infection
symptoms and altering gut microbiome in COVID-19 infection.
NCT04399252 Effect of Lactobacillus on the Microbiome of Household
Randomized trial assessing the effect of Lactobacillus rhamnosus GG on the
Contacts Exposed to COVID-19
microbiome of household contacts of COVID-19 patients.
NCT04540406 NBT-NM108 as an Early Treatment for Suspected or
Open-label, randomized controlled trial assessing the feasibility and effectiveness of a
Conﬁrmed Symptomatic COVID-19 Patients (COVGUT20)
novel botanical-based ﬁxed-combination drug to modulate the gut microbiota and
treat early-stage suspected or conﬁrmed symptomatic COVID-19 patients.
NCT04390477 Study to Evaluate the Effect of a Probiotic in COVID-19
Prospective case–control pilot study to evaluate the possible effect of a probiotic
mixture in the improvement of symptoms, the reduction in the number of days of
hospitalization and the increase in the percentage of patients with negative PCR after
infection with the coronavirus SARS-CoV-2
NCT04366089 Oxygen-Ozone as Adjuvant Treatment in Early Control of
Randomized trial evaluating the adjuvant use of oxygen ozone therapy plus probiotic
COVID-19 Progression and Modulation of the Gut Microbial
supplementation in addition to standard of care in the early control of disease
Flora (PROBIOZOVID)
progression in patients with COVID-19.
NCT04877704 Symprove (Probiotic) as an add-on to COVID-19 Management Randomized trial studying outcomes in COVID-19 patients treated with adjunctive
probiotics for 3 months. A sub-study, subject to participant consent, will also collect
biological samples for comparative analysis.
NCT04734886 The Effect of Probiotic Supplementation on SARS-CoV-2
Randomized trial assessing the impact of L. reuteri DSM 17938 on SARS-CoV-2Antibody Response After COVID-19
speciﬁc antibody response upon and after infection in healthy adults, in addition to
inﬂammatory markers, symptom severity and duration.
NCT04390477 The Intestinal Microbiota as a Therapeutic Target in
Pilot study on the effect of a probiotic mixture in the improvement of symptoms, the
Hospitalized Patients With COVID-19 Infection
reduction in the number of days of hospitalization and the increase in the percentage
of patients with negative PCR after infection with SARS-CoV-2.
NCT04366180 Multicentric Study to Assess the Effect of Consumption of
Randomized controlled trial evaluating the effects of Lactobacillus coryniformis K8
Lactobacillus Coryniformis K8 on Healthcare Personnel
consumption on the incidence and severity of COVID-19 in health workers exposed to
Exposed to COVID-19
the SARS-CoV-2 virus.

(Continued)
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TABLE 3 | Continued
A. Ongoing
studies
B.
Ongoingobservational
studies utilizing
microbiota as therapeutic target
Trial number

Title

NCT04907877 Role of Nutritional Support With Probiotics in Adult Outpatients
With Symptomatic COVID-19: a Randomized Dietary Study
NCT04854941 Efﬁcacy of Probiotics (Lactobacillus Rhamnosus,
Biﬁdobacterium Biﬁdum, Biﬁdobacterium Longum Subsp.
Infantis and Biﬁdobacterium Longum) in the Treatment of
Hospitalised Patients With Novel Coronavirus Infection
NCT04798677 Efﬁcacy and Tolerability of ABBC1 in Volunteers Receiving the
Inﬂuenza or Covid-19 Vaccine
NCT04847349 Live Microbials to Boost Anti-SARS-CoV-2 Immunity Clinical
Trial (Live BASIC Trial)
NCT04756466 Effect of the Consumption of a Lactobacillus Strain on the
Incidence of Covid-19 in the Elderly
NCT04922918 Administration of Ligilactobacillus salivarius MP101 in an
Elderly Nursing Home During the COVID Pandemics
NCT04793997 Covid-19 Primary Care Support With Microbiome Therapy

NCT04884776 Modulation of Gut Microbiota to Enhance Health and Immunity
of Vulnerable Individuals During COVID-19 Pandemic
NCT04824222 The Impact of Fecal Microbiota Transplantation as an
Immunomodulation on the Risk Reduction of COVID-19
Disease Progression With Escalating Cytokine Storm and
Inﬂammatory Parameters (FeMToCOVID)

Summary
Randomized controlled trial comparing the effect of a probiotic mixture of biﬁdo- and
lactobacteria on COVID-19 severity and subsequent immune response.
Randomized controlled open-label study analyzing the effect of a probiotic mixture
consisting of L. rhamnosus, B. biﬁdum, B, longum subsp. infantis and B. longum on
SARS-Cov-2 infection outcomes.
Randomized, single-center trial comparing the immune response of volunteers who
had nutritional supplementation with a probiotic formulation while receiving the
inﬂuenza or COVID-19 vaccine.
Pilot study on the efﬁcacy of a combination of live probiotics on antibody titers,
symptom improvement and reinfection risk in unvaccinated persons previously
infected with SARS-CoV-2.
Multi-center randomized controlled trial evaluating the effect of a probiotic strain on the
incidence and severity of COVID-19, as well as the immune response to COVID-19
vaccination, in an elderly population living in a nursing home.
Clinical trial investigating the effect of Ligilactobacillus salivarius MP101 on the
functional, cognitive, and nutritional status, as well as nasal and fecal inﬂammatory
proﬁles of elderly people living in a nursing home highly affected by COVID-19.
Randomized controlled trial evaluating the efﬁcacy of a probiotic throat spray in
reducing symptoms COVID-19 in patients with mild to moderate symptoms.
Secondary outcome of whether the spray can prevent transmission of the SARS-CoV2 virus to household members.
Randomized controlled trial studying a probiotic formula in enhancing immunity and
reducing hospitalization in elderly and diabetic patients.
Randomized phase II (open-label) and phase III (double-blinded) trial evaluating the
effect of fecal microbiota transplantation (FMT) as an immunomodulator in addition to
standard therapy on the risk reduction of disease progression in COVID-19 with
escalating cytokine storm and inﬂammatory markers.

Extracted from the database of clinicaltrials.org on June 19, 2021.

mounting for gut dysbiosis as a predisposing factor for severe
COVID-19, through a leaky gut phenomenon and resultant
spillage of bacterial products and toxins. Evidence is emerging
that the degree of dysbiosis correlates with the severity of COVID19 illness. This behooves us to explore potentially preventive and
therapeutic targets, such as dietary intervention and probiotics.
Several ongoing trials are evaluating various pathogenic routes and
therapeutic approaches. While efforts for direct anti-viral agents
and vaccines are of prime signiﬁcance, the gut–lung axis could still
hold therapeutic potential.

gut more clearly with biomarkers and cutoff criteria, to also
enable clariﬁcation on whether patients who have developed an
inﬂammatory cascade are still amenable to therapeutic gut
microbiota modulation.
Besides exploration of any potential role in the management of
COVID-19, long-term consequences of gut dysbiosis should also be
explored with longitudinal follow-up (Table 2). A search of ongoing
clinical trials at the US National Library of Medicine reveals 24
registered studies assessing microbiota-targeted therapeutic
options (Table 3).

CONCLUSION
AUTHOR CONTRIBUTIONS

The role of resident gut microbiota in other respiratory illnesses
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senescence-driven gut dysbiosis. Increasingly, evidence is

IH and MBA: study concept. IH and MBA: literature search. IH,
GY, and MBA: manuscript writing. MAA: critical revisions and
intellectual content. MBA: supervision. All authors contributed
to the article and approved the submitted version.
2. The Lancet Respiratory Medicine Realising the Potential of SARS-CoV-2 Vaccinesa Long Shot? Lancet Respir Med (2021). doi: 10.1016/S2213-2600(21)00045-X
3. Yuen K-S, Ye Z-W, Fung S-Y, Chan C-P, Jin D-Y. SARS-CoV-2 and COVID19: The Most Important Research Questions. Cell Biosci (2020) 10:40. doi:
10.1186/s13578-020-00404-4

REFERENCES
1. Wang C, Horby PW, Hayden FG, Gao GF. A Novel Coronavirus Outbreak of
Global Health Concern. Lancet (London England) (2020) 395:470–3. doi:
10.1016/S0140-6736(20)30185-9

Frontiers in Immunology | www.frontiersin.org

10

October 2021 | Volume 12 | Article 765965

Hussain et al.

Gut Microbiome and COVID-19

25. Liang S, Wu X, Hu X, Wang T, Jin F. Recognizing Depression From the
Microbiota–Gut–Brain Axis. Int J Mol Sci (2018) 19:1592. doi: 10.3390/
ijms19061592
26. Budden KF, Gellatly SL, Wood DLA, Cooper MA, Morrison M, Hugenholtz P,
et al. Emerging Pathogenic Links Between Microbiota and the Gut-Lung Axis.
Nat Rev Microbiol (2017) 15:55–63. doi: 10.1038/nrmicro.2016.142
27. Enaud R, Prevel R, Ciarlo E, Beauﬁls F, Wieërs G, Guery B, et al. The GutLung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and
Inter-Kingdom Crosstalks. Front Cell Infect Microbiol (2020) 10:9. doi:
10.3389/fcimb.2020.00009
28. Grier A, McDavid A, Wang B, Qiu X, Java J, Bandyopadhyay S, et al.
Neonatal Gut and Respiratory Microbiota: Coordinated Development
Through Time and Space. Microbiome (2018) 6:193. doi: 10.1186/s40168018-0566-5
29. Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, Housman ML,
et al. Serial Analysis of the Gut and Respiratory Microbiome in Cystic Fibrosis
in Infancy: Interaction Between Intestinal and Respiratory Tracts and Impact
of Nutritional Exposures. MBio (2012) 3. doi: 10.1128/mBio.00251-12
30. Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Falkowski NR,
Huffnagle GB, et al. Bacterial Topography of the Healthy Human Lower
Respiratory Tract. MBio (2017) 8. doi: 10.1128/mBio.02287-16
31. Kraft SC, Earle RH, Roesler M, Esterly JR. Unexplained Bronchopulmonary
Disease With Inﬂammatory Bowel Disease. Arch Intern Med (1976) 136:454–
9. doi: 10.1001/archinte.1976.03630040056012
32. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al.
Microbiota Regulates Immune Defense Against Respiratory Tract Inﬂuenza A
Virus Infection. Proc Natl Acad Sci U S A (2011) 108:5354–9. doi: 10.1073/
pnas.1019378108
33. Marsland BJ, Trompette A, Gollwitzer ES. The Gut-Lung Axis in Respiratory
Disease. Ann Am Thorac Soc (2015) 12 Suppl 2:S150–6. doi: 10.1513/
AnnalsATS.201503-133AW
34. Deriu E, Boxx GM, He X, Pan C, Benavidez SD, Cen L, et al. Inﬂuenza Virus
Affects Intestinal Microbiota and Secondary Salmonella Infection in the Gut
Through Type I Interferons. PloS Pathog (2016) 12:e1005572. doi: 10.1371/
journal.ppat.1005572
35. Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory Viral InfectionInduced Microbiome Alterations and Secondary Bacterial Pneumonia. Front
Immunol (2018) 9:2640. doi: 10.3389/ﬁmmu.2018.02640
36. Wang J, Li F, Wei H, Lian Z-H, Sun R, Tian Z. Respiratory Inﬂuenza Virus
Infection Induces Intestinal Immune Injury via Microbiota-Mediated Th17
Cell-Dependent Inﬂammation. J Exp Med (2014) 211:2397–410. doi: 10.1084/
jem.20140625
37. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple Organ
Infection and the Pathogenesis of SARS. J Exp Med (2005) 202:415–24. doi:
10.1084/jem.20050828
38. Dickson RP, Singer BH, Newstead MW, Falkowski NR, Erb-Downward JR,
Standiford TJ, et al. Enrichment of the Lung Microbiome With Gut Bacteria in
Sepsis and the Acute Respiratory Distress Syndrome. Nat Microbiol (2016)
1:16113. doi: 10.1038/nmicrobiol.2016.113
39. Bartley JM, Zhou X, Kuchel GA, Weinstock GM, Haynes L. Impact of Age,
Caloric Restriction, and Inﬂuenza Infection on Mouse Gut Microbiome: An
Exploratory Study of the Role of Age-Related Microbiome Changes on
Inﬂuenza Responses. Front Immunol (2017) 8:1164. doi: 10.3389/ﬁmmu.
2017.01164
40. Yildiz S, Mazel-Sanchez B, Kandasamy M, Manicassamy B, Schmolke M.
Inﬂuenza A Virus Infection Impacts Systemic Microbiota Dynamics and
Causes Quantitative Enteric Dysbiosis. Microbiome (2018) 6:9. doi: 10.1186/
s40168-017-0386-z
41. Groves HT, Cuthbertson L, James P, Moffatt MF, Cox MJ, Tregoning JS.
Respiratory Disease Following Viral Lung Infection Alters the Murine Gut
Microbiota. Front Immunol (2018) 9:182. doi: 10.3389/ﬁmmu.2018.00182
42. Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis-Owen SAG, Homola D,
et al. Outgrowth of the Bacterial Airway Microbiome After Rhinovirus
Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Respir Crit
Care Med (2013) 188:1224–31. doi: 10.1164/rccm.201302-0341OC
43. Gu L, Deng H, Ren Z, Zhao Y, Yu S, Guo Y, et al. Dynamic Changes in the
Microbiome and Mucosal Immune Microenvironment of the Lower

4. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19
Cytokine Storm; What We Know So Far. Front Immunol (2020) 11:1446. doi:
10.3389/ﬁmmu.2020.01446
5. Abid MB, Mughal M, Abid MA. Coronavirus Disease 2019 (COVID-19) and
Immune-Engaging Cancer Treatment. JAMA Oncol (2020) 6:1529–30. doi:
10.1001/jamaoncol.2020.2367
6. Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly R, et al.
Clinical Characteristics and Outcomes of COVID-19 in Haematopoietic
Stem-Cell Transplantation Recipients: An Observational Cohort Study.
Lancet Haematol (2021) 9:117. doi: 10.1016/S2352-3026(20)30429-4
7. Jordan RE, Adab P, Cheng KK. Covid-19: Risk Factors for Severe Disease and
Death. BMJ (2020) 368:m1198. doi: 10.1136/bmj.m1198
8. Abid MA, Nunley L, Abid MB. Could Coronavirus Disease 2019 (COVID19) Render Natural Immunity to Re-Infections? A Spotlight on the
Therapeutic Pipeline. Front Immunol (2020) 11:1294. doi: 10.3389/
ﬁmmu.2020.01294
9. Hoong CWS, Hussain I, Aravamudan VM, Phyu EE, Lin JHX, Koh H.
Obesity Is Associated With Poor Covid-19 Outcomes: A Systematic Review
and Meta-Analysis. Horm Metab Res (2021) 53:85–93. doi: 10.1055/a-13262125
10. Viner RM, Whittaker E. Kawasaki-Like Disease: Emerging Complication
During the COVID-19 Pandemic. Lancet (London England) (2020)
395:1741–3. doi: 10.1016/S0140-6736(20)31129-6
11. Zmora N, Suez J, Elinav E. You Are What You Eat: Diet, Health and the Gut
Microbiota. Nat Rev Gastroenterol Hepatol (2019) 16:35–56. doi: 10.1038/
s41575-018-0061-2
12. Abid MB. Could the Menagerie of the Gut Microbiome Really Cure Cancer?
Hope or Hype. J Immunother Cancer (2019) 7:92. doi: 10.1186/s40425-0190561-9
13. Dang AT, Marsland BJ. Microbes, Metabolites, and the Gut-Lung
Axis. Mucosal Immunol (2019) 12:843–50. doi: 10.1038/s41385-0190160-6
14. McAleer JP, Kolls JK. Contributions of the Intestinal Microbiome in Lung
Immunity. Eur J Immunol (2018) 48:39–49. doi: 10.1002/eji.201646721
15. Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, et al. The
Host Microbiome Regulates and Maintains Human Health: A Primer and
Perspective for Non-Microbiologists. Cancer Res (2017) 77:1783–812. doi:
10.1158/0008-5472.CAN-16-2929
16. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A,
et al. What Is the Healthy Gut Microbiota Composition? A Changing
Ecosystem Across Age, Environment, Diet, and Diseases. Microorganisms
(2019) 7. doi: 10.3390/microorganisms7010014
17. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A Human
Gut Microbial Gene Catalogue Established by Metagenomic Sequencing.
Nature (2010) 464:59–65. doi: 10.1038/nature08821
18. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery
E, et al. Composition, Variability, and Temporal Stability of the Intestinal
Microbiota of the Elderly. Proc Natl Acad Sci USA (2011) 108 Suppl:4586–91.
doi: 10.1073/pnas.1000097107
19. Kau AL, Ahern PP, Grifﬁn NW, Goodman AL, Gordon JI. Human Nutrition,
the Gut Microbiome and the Immune System. Nature (2011) 474:327–36. doi:
10.1038/nature10213
20. Guh AY, Kutty PK. Clostridioides Difﬁcile Infection. Ann Intern Med (2018)
169:ITC49–64. doi: 10.1016/j.ebiom.2019.11.051
21. Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of Gut
Microbiota in Type 2 Diabetes Pathophysiology. EBioMedicine (2020)
51:102590. doi: 10.1016/j.ebiom.2019.11.051
22. Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, et al.
Microbiota-Driven Gut Vascular Barrier Disruption Is a Prerequisite for nonAlcoholic Steatohepatitis Development. J Hepatol (2019) 71:1216–28. doi:
10.1016/j.jhep.2019.08.005
23. Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Intestinal Microbiota in
Cardiovascular Health and Disease: JACC State-of-the-Art Review. J Am Coll
Cardiol (2019) 73:2089–105. doi: 10.1016/j.jacc.2019.03.024
24. Dinan TG, Cryan JF. Gut Instincts: Microbiota as a Key Regulator of Brain
Development, Ageing and Neurodegeneration. J Physiol (2017) 595:489–503.
doi: 10.1113/JP273106

Frontiers in Immunology | www.frontiersin.org

11

October 2021 | Volume 12 | Article 765965

Hussain et al.

44.

45.

46.

47.

48.

49.

50.

51.

52.

53.

54.
55.

56.

57.

58.

59.

60.

61.

62.

63.

Gut Microbiome and COVID-19

64. Newsome RC, Gauthier J, Hernandez MC, Abraham GE, Robinson TO,
Williams HB, et al. The Gut Microbiome of COVID-19 Recovered Patients
Returns to Uninfected Status in a Minority-Dominated United States Cohort.
Gut Microbes (2021) 13:1–15. doi: 10.1080/19490976.2021.1926840
65. Lv L, Jiang H, Chen Y, Gu S, Xia J, Zhang H, et al. The Faecal Metabolome in
COVID-19 Patients is Altered and Associated With Clinical Features and Gut
Microbes. Anal Chim Acta (2021) 1152:338267. doi: 10.1016/j.aca.2021.
338267
66. Zuo T, Liu Q, Zhang F, Lui GC-Y, Tso EY, Yeoh YK, et al. Depicting SARSCoV-2 Faecal Viral Activity in Association With Gut Microbiota Composition
in Patients With COVID-19. Gut (2021) 70:276–84. doi: 10.1136/gutjnl-2020322294
67. Tsikala Vafea M, Chander B. Chest CT Findings in Asymptomatic Cases With
COVID-19: A Systematic Review and Meta-Analysis. Clin Radiol (2020)
75:876.e33–876.e39. doi: 10.1016/j.mehy.2020.110209
68. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are
Asymptomatic: A Systematic Review. Ann Intern Med (2021) 174:655–62. doi:
10.7326/M20-6976
69. Kumar P, Chander B. COVID 19 Mortality: Probable Role of Microbiome to
Explain Disparity. Med Hypotheses (2020) 144:110209. doi: 10.1016/
j.mehy.2020.110209
70. Bana B, Cabreiro F. The Microbiome and Aging. Annu Rev Genet (2019)
53:239–61. doi: 10.1146/annurev-genet-112618-043650
71. Wilkins LJ, Monga M, Miller AW. Deﬁning Dysbiosis for a Cluster of Chronic
Diseases. Sci Rep (2019) 9:12918. doi: 10.1038/s41598-019-49452-y
72. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological Findings
of COVID-19 Associated With Acute Respiratory Distress Syndrome. Lancet
Respir Med (2020) 8:420–2. doi: 10.1016/S2213-2600(20)30076-X
73. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T-Cells and
Inﬂammatory Monocytes Incite Inﬂammatory Storms in Severe COVID-19
Patients. Natl Sci Rev (2020) 7:998–1002. doi: 10.1093/nsr/nwaa041
74. Abid MB, Koh CJ. Probiotics in Health and Disease: Fooling Mother Nature?
Infection (2019) 47:911–7. doi: 10.1007/s15010-019-01351-0
75. Ratajczak W, Rył A, Mizerski A, Walczakiewicz K, Sipak O, Laszczyń ska M,
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